Lamiridosin - EU

Lamiridosin is an oral supplement derived from the Corporation’s “Liver Health” formulation and is being prepared for worldwide market launches in late 2010 and early 2011. Preclinical research and observational studies support ongoing research and development as a supplement to existing therapies for populations with chronic liver maladies. Clinical trials with Lamiridosin are planned for the first half of 2010.

The active ingredients contained in this food supplement are Flavonoids, Catechins and Lamiridosin. Flavonoids are plant polyphenols that have shown many beneficial effects due to their properties as antioxidants, chelating free radicals. Flavonoids in turn have given positive responses about his ability antiallergic, and immunomodulatory and antiproliferative. Catechins are flavonoids whose main properties include that of acting as an antiinflammatory, immunoregulatory and hepatoprotective. The Lamiridosin is aglicano of iridoid, which has shown in in vitro and in vivo hepatoprotective and antiviral some capacity against hepatitis C.